The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders
Chronic cerebral hypoperfusion (CCH) represents a key pathogenic contributor to neurocognitive disorders. It can lead to multifaceted pathological alterations including neuroinflammation, neuronal apoptosis, blood–brain barrier disruption, synaptic plasticity deficits, and mitochondrial dysfunction....
Saved in:
| Main Authors: | Junchen Si, Kai Yu, Jiheng Hao, Jiyue Wang, Liyong Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-04-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864251332035 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01) -
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01) -
Mechanism of glucagon-like peptide-1 receptor agonist in the treatment of obesity and food addiction
by: LIU Luyao, LI Linwei, WANG Chen, DI Jianzhong
Published: (2025-06-01) -
Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Mechanisms, Efficacy, and Safety
by: Michał Stasiak, et al.
Published: (2025-06-01) -
Research progress on mechanisms of glucagon-like peptide-1 receptor agonists in diabetic retinopathy
by: HE Cuihuan, SHI Derong, SUN Dandan, LI Yurui, XIA Guanghao
Published: (2025-02-01)